Skip to main content

Advertisement

SpringerLink
Log in

ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Author notes

  1. Ankit Dhiman, Charles C. Vining, Daniel V. T. Catenacci, Kiran K. Turaga have contributed equally.

Authors and Affiliations

  1. Section of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago Medicine, Chicago, IL, USA

    Ankit Dhiman MBBS, Charles C. Vining MD, Hunter D. D. Witmer MD, Divya Sood MD, Kevin K. Roggin MD, Mitchell C. Posner MD, Oliver S. Eng MD & Kiran K. Turaga MD, MPH

  2. Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL, USA

    Ardaman Shergill MD, Hedy Kindler MD, Chih-Yi Liao MD, Blasé Polite MD & Daniel V. T. Catenacci MD

  3. Department of Radiology, University of Chicago, Chicago, IL, USA

    Osmanuddin S. Ahmed MD

  4. Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA

    Stanley Liauw MD, PhD, Sean Pitroda MD & Ralph Weichselbaum MD

  5. The Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA

    Stanley Liauw MD, PhD, Sean Pitroda MD & Ralph Weichselbaum MD

  6. Department of Public Health Sciences, University of Chicago, Chicago, IL, USA

    Theodore Karrison PhD

Authors
  1. Ankit Dhiman MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles C. Vining MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hunter D. D. Witmer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Divya Sood MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ardaman Shergill MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hedy Kindler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kevin K. Roggin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitchell C. Posner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Osmanuddin S. Ahmed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stanley Liauw MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sean Pitroda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chih-Yi Liao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Theodore Karrison PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ralph Weichselbaum MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Blasé Polite MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Oliver S. Eng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Daniel V. T. Catenacci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Kiran K. Turaga MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiran K. Turaga MD, MPH.

Ethics declarations

Daniel V. T. Catenacci, MD reports personal fees for Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus Biosciences, Tempus, Guardant Health, Archer, and Natera. Osmanuddin Ahmed reports advisory board for Johnson and Johnson, Boston Scientific, and Medtronic; speaking fees for Agron Medical, Canon Medical, Philips, and Penumbra; and a research grant from Canon Medical. Sean Pitroda: two patents for methods and kits for diagnosis and triage of patients with colorectal liver metastases are pending. Andy Liao received consultation honoraria for Ispen, Exelixis, Eisai, Genentech, QED Therapeutics, Incyte, Lexicon, BluePrints Medicine, Transthera, and Histosonics Ralph Weichselbaum has stock and other ownership interests with Boost Therapeutics, Immvira LLC, Reflexion Pharmaceuticals, Coordination Pharmaceuticals Inc., Magi Therapeutics, and Oncosenescence. He has served in a consulting or advisory role for Aettis Inc., Astrazeneca, Coordination Pharmaceuticals, Genus, Merck Serono S.A., Nano proteagen, NKMax America Inc, Shuttle Pharmaceuticals, and Highlight Therapeutics, S.L. He has research grants with Varian and Regeneron. He has received compensation including travel, accommodations, or expense reimbursement from Astrazeneca, Boehringer Ingelheim LTD., and Merck Serono S.A. All other authors have no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhiman, A., Vining, C.C., Witmer, H.D.D. et al. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol 29 (Suppl 3), 616–617 (2022). https://doi.org/10.1245/s10434-022-11448-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11448-w

Search

Navigation